Prevents pregnancy. ANDA 91204, held by Novast Labs Ltd. Ethinyl Estradiol; Norethindrone.
As of Nov 16, 2026, ANDA 91204 (Wera), held by Novast Labs Ltd, was first approved by FDA on Mar 27, 2012, with 5 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Necon Tablets are indicated for the prevention of pregnancy in women who elect to use this product as a method of contraception. Oral contraceptives are highly effective. Table 1 lists the typical accidental pregnancy rates for users of combined oral contraceptives and other methods of contraception. The efficacy of these contraceptive methods, except sterilization, the IUD, and the NORPLANT System depends upon the reliability with which they are used. Correct and consistent use of methods can result in lower failure rates.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 27, 2012 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Wera0.035MG;0.5MG · tablet;oral-28 | Ethinyl Estradiol; Norethindrone | Rx |
| Apr 29, 2022 | Supplement 9Labeling · Standard review | Approved | None posted |
| Feb 28, 2022 | Supplement 5Labeling · Standard review | Approved | None posted |
| Feb 28, 2022 | Supplement 3Labeling · Standard review | Approved | None posted |
| Sep 29, 2015 | Supplement 2Labeling · Standard review | Approved | None posted |
| Sep 29, 2015 | Supplement 1Labeling | Approved | None posted |
| Mar 27, 2012 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters